Research programme: CD200-based therapeutics - Trillium Therapeutics Inc

Drug Profile

Research programme: CD200-based therapeutics - Trillium Therapeutics Inc

Alternative Names: Anti-CD 200 monoclonal antibodies; CD200 fusion protein; CD200Fc; TTI 200.7

Latest Information Update: 29 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trillium Therapeutics Inc
  • Class Monoclonal antibodies; Proteins
  • Mechanism of Action CD200 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Immunological disorders; Transplant rejection

Most Recent Events

  • 29 Dec 2017 CD200-based therapeutics are still in preclinical trials for Cancer in Canada (Parenteral)
  • 09 Dec 2017 Pharmacodynamics data from preclinical trials in Cancer presented at the 59th Annual Meeting and Exposition of the American Society of Haematology
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top